Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shalby Ltd. ( (IN:SHALBY) ).
Shalby Limited has announced that its Krishna unit in Ahmedabad has secured a five-year approval to conduct kidney transplants, effective from 9 April 2026. The authorization allows the hospital to offer advanced renal transplant procedures as part of its broader multi-speciality care portfolio.
The new approval is expected to improve access to life-saving transplant services for patients in and around Ahmedabad, reducing the need for long-distance travel and lowering related costs. It also strengthens continuity of care, as patients can receive comprehensive pre- and post-transplant management within a single facility, enhancing Shalby’s role as a regional healthcare provider.
More about Shalby Ltd.
Shalby Limited operates a network of multi-speciality hospitals in India, with a strong presence in Ahmedabad, Gujarat. The group focuses on providing advanced medical and surgical care, and its Krishna unit in Ahmedabad is part of its expanding portfolio of tertiary healthcare services aimed at serving regional communities.
Average Trading Volume: 7,966
Technical Sentiment Signal: Sell
Current Market Cap: 16.58B INR
For an in-depth examination of SHALBY stock, go to TipRanks’ Overview page.